Patents Assigned to Japan Stent Technology Co., Ltd.
  • Patent number: 9040111
    Abstract: A method of making a stent, including preparing a solution containing a composition, the composition comprising a biodegradable polymer and a vascular intimal hyperplasia inhibitor of a kind, including argatroban, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the vascular intimal hyperplasia inhibitor being within the range of 8:2 to 3:7, the composition dissolved in a solvent selected from the group consisting of a mixture of a lower alkyl ketone and methanol, a mixture of a lower alkyl ester and methanol or a mixture of a lower halogenated hydrocarbon and methanol; coating at least an outer surface of a stent body of a cylindrical configuration having outer and inner surfaces with a diamond-like thin film coated on the surfaces; and after the coating, removing the solvent to complete a first coated layer.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: May 26, 2015
    Assignees: JAPAN STENT TECHNOLOGY CO., LTD., TOKAI UNIVERSITY EDUCATIONAL SYSTEM, TOYO ADVANCED TECHNOLOGIES CO., LTD.
    Inventors: Ikuo Omura, Zhen Yu Jin, Shuzo Yamashita, Hiroo Iwata, Akira Mochizuki
  • Patent number: 8968392
    Abstract: A method of inhibiting vascular intimal hyperplasia including: placing a stent within a blood vessel, the stent having a stent body of a cylindrical configuration having outer and inner surfaces with a diamond-like thin film coated on the surfaces, a first coated layer coating at least the outer surface of the stent body, the first coated layer being prepared of a first composition comprising a biodegradable polymer and a vascular intimal hyperplasia inhibitor of a kind, comprising argatroban, which does not inhibit proliferation of endothelial cells, the weight composition ratio of the polymer to the vascular intimal hyperplasia inhibitor being within the range of 8:2 to 7:3, and a second coated layer; and causing argatroban to be released from the stent to thereby inhibit the vascular intimal hyperplasia without inhibiting proliferation of endothelial cells.
    Type: Grant
    Filed: July 30, 2012
    Date of Patent: March 3, 2015
    Assignees: Japan Stent Technology Co., Ltd., Tokai University Educational System, Toyo Advanced Technologies Co., Ltd., Hiroo Iwata
    Inventors: Ikuo Omura, Zhen Yu Jin, Shuzo Yamashita, Hiroo Iwata, Akira Mochizuki
  • Patent number: 8882827
    Abstract: The stent comprises a tubular body comprising a plurality of ring units arranged in the axis direction and bridged by a connecting element. Each of the units comprises a plurality of cells connected with each other, each of the cells having a U-shaped form comprising two linear parts and a circular arc part therebetween, and opening toward one end. The ring units comprise first and second units alternatively arranged and the oppositely disposed cells of the first and second units are only partly bridged by the connecting elements. The shapes of the cells of the first and second units are axisymmetrical about the connecting element. The curvature radius of the top of the arc constituting the arc part is 1.1 and 1.5 times larger than that of each of the tangent circles formed at the edges of two linear parts of the cell on the circular arc part side.
    Type: Grant
    Filed: September 16, 2010
    Date of Patent: November 11, 2014
    Assignee: Japan Stent Technology Co., Ltd.
    Inventors: Hai Quan Feng, Suguru Kishimoto, Jun Kubota, Minoru Asahara
  • Patent number: 8652199
    Abstract: To provide a stent which holds various performances such as deliverability, prevention of restenosis, flexible shape conformability, and so on and is therefore adaptable not only to a bile duct but also to a blood vessel system such as a tortuous coronary artery substantially without causing restenosis. A stent with an autonomic function is made of a Ti—Ni based shape memory alloy and has a maximum expanding force at a center portion in its lengthwise direction.
    Type: Grant
    Filed: May 23, 2006
    Date of Patent: February 18, 2014
    Assignees: NEC Tokin Corporation, Tohoku University, Japan Stent Technology Co., Ltd.
    Inventors: Michihide Ozawa, Kiyoshi Yamauchi, Yuji Sutou, Takamitsu Takagi, Shuzou Yamashita, Kouji Mori
  • Patent number: 8641756
    Abstract: A stent includes a stent body of a cylindrical configuration having outer and inner surfaces, a first coated layer coating at least the outer surface, and a second coated layer coating substantially completely over the first coated layer. The first coated layer is prepared of a first composition comprising a polymer and a vascular intimal hyperplasia inhibitor (preferably argatroban) of a kind, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the inhibitor being within the range of 8:2 to 3:7. On the other hand, the second coated layer is prepared of a polymer alone or a second composition comprising a polymer and a drug, the weight compositional ratio of the drug to 80% by weight of the polymer being less than 20% by weight.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: February 4, 2014
    Assignees: Japan Stent Technology Co., Ltd., Tokai University Educational System, Toyo Advanced Technologies Co., Ltd., Hiroo Iwata Institute for Frontier Medical Sciences, Kyoto University
    Inventors: Ikuo Omura, Zhen Yu Jin, Shuzo Yamashita, Hiroo Iwata, Akira Mochizuki
  • Patent number: 8591571
    Abstract: A drug-eluting stent comprises a coated layer prepared of a composition comprising a polymer and a drug, the coated layer being a single coated layer with the composition, or comprises a first coated layer prepared of the above composition and a second coated layer with a polymer alone, the first coated layer being coated by the second coated layer. The drug is a vascular intimal hyperplasia inhibitor which does not inhibit proliferation of endothelial cells, and the composition substantially excludes a lipid-soluble low-molecular compound. The polymer in the first layer is a copolymer of lactic acid (monomer A) and a terminal hydroxy straight alkyl carboxylic acid having 3 to 8 carbon atoms, and, if the second coated layer is formed, the polymer in the second coated layer is a poly(lactic acid), a poly(glycolic acid), or a poly(lactic acid-co-glycolic acid).
    Type: Grant
    Filed: August 25, 2011
    Date of Patent: November 26, 2013
    Assignee: Japan Stent Technology Co., Ltd.
    Inventors: Ikuo Omura, Zhen Yu Jin
  • Patent number: 8591782
    Abstract: A stent comprising a tubular stent matrix of which diameter is extendable and a flexible polymer layer covering the stent matrix. The polymer layer is closely attached to and covers the entire surface of the stent matrix. Since the flexible polymer layer closely covers the entire surface of the stent matrix not only the outer periphery of the stent matrix, the stent has no problem of causing allergic to metal, stimulus of tissues due to metal, and rust development. Since the inner periphery of the stent is a flat and smooth surface covered by the polymer layer without convexes and concaves, the formation of thrombus can be inhibited well. There is no problem of drift between the polymer layer and the stent matrix, thereby maintaining the positional relationship between the stent matrix and the polymer layer before and after the expansion of the stent.
    Type: Grant
    Filed: August 20, 2003
    Date of Patent: November 26, 2013
    Assignees: National Cerebral and Cardiovascular Center, Japan Stent Technology Co., Ltd.
    Inventors: Yasuhide Nakayama, Shogo Nishi, Yasushi Nemoto, Yoshihiro Okamoto
  • Patent number: 8435287
    Abstract: A stent includes a tubular stent body 11, a diamond-like carbon film 12 formed on the surface of the stent body 11 and having an activated surface, and a polymer layer 13 immobilized on the surface of the diamond-like carbon film. The polymer layer 13 contains a drug 14 having an effect to prevent restenosis, and the drug 14 is gradually released from the polymer layer 13.
    Type: Grant
    Filed: January 15, 2007
    Date of Patent: May 7, 2013
    Assignees: Toyo Advanced Technologies Co., Ltd., Japan Stent Technology Co., Ltd
    Inventors: Tatsuyuki Nakatani, Keishi Okamoto, Shuzo Yamashita, Ikuo Komura, Koji Mori
  • Patent number: 8409272
    Abstract: A stent includes a stent body of a cylindrical configuration having outer and inner surfaces, a first coated layer coating at least the outer surface, and a second coated layer coating substantially completely over the first coated layer. The first coated layer is prepared of a first composition comprising a polymer and a vascular intimal hyperplasia inhibitor (preferably argatroban) of a kind, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the inhibitor being within the range of 8:2 to 3:7. On the other hand, the second coated layer is prepared of a polymer alone or a second composition comprising a polymer and a drug, the weight compositional ratio of the drug to 80% by weight of the polymer being less than 20% by weight.
    Type: Grant
    Filed: September 3, 2008
    Date of Patent: April 2, 2013
    Assignees: Japan Stent Technology Co., Ltd., Tokai University Educational System, Toyo Advanced Technologies Co., Ltd.
    Inventors: Ikuo Omura, Zhen Yu Jin, Shuzo Yamashita, Hiroo Iwata, Akira Mochizuki
  • Publication number: 20130018455
    Abstract: A method of inhibiting vascular intimal hyperplasia including: placing a stent within a blood vessel, the stent having a stent body of a cylindrical configuration having outer and inner surfaces with a diamond-like thin film coated on the surfaces, a first coated layer coating at least the outer surface of the stent body, the first coated layer being prepared of a first composition comprising a biodegradable polymer and a vascular intimal hyperplasia inhibitor of a kind, comprising argatroban, which does not inhibit proliferation of endothelial cells, the weight composition ratio of the polymer to the vascular intimal hyperplasia inhibitor being within the range of 8:2 to 7:3, and a second coated layer; and causing argatroban to be released from the stent to thereby inhibit the vascular intimal hyperplasia without inhibiting proliferation of endothelial cells.
    Type: Application
    Filed: July 30, 2012
    Publication date: January 17, 2013
    Applicants: JAPAN STENT TECHNOLOGY CO., LTD., HIROO IWATA, TOYO ADVANCED TECHNOLOGIES CO., LTD., TOKAI UNIVERSITY EDUCATIONAL SYSTEM
    Inventors: Ikuo Omura, Zhen Yu Jin, Shuzo Yamashita, Hiroo Iwata, Akira Mochizuki
  • Publication number: 20120310329
    Abstract: A stent includes a stent body of a cylindrical configuration having outer and inner surfaces, a first coated layer coating at least the outer surface, and a second coated layer coating substantially completely over the first coated layer. The first coated layer is prepared of a first composition comprising a polymer and a vascular intimal hyperplasia inhibitor (preferably argatroban) of a kind, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the inhibitor being within the range of 8:2 to 3:7. On the other hand, the second coated layer is prepared of a polymer alone or a second composition comprising a polymer and a drug, the weight compositional ratio of the drug to 80% by weight of the polymer being less than 20% by weight.
    Type: Application
    Filed: June 8, 2012
    Publication date: December 6, 2012
    Applicants: JAPAN STENT TECHNOLOGY CO., LTD., HIROO IWATA, TOYO ADVANCED TECHNOLOGIES CO., LTD., TOKAI UNIVERSITY EDUCATIONAL SYSTEM
    Inventors: Ikuo OMURA, Zhen Yu JIN, Shuzo YAMASHITA, Hiroo IWATA, Akira MOCHIZUKI
  • Publication number: 20110313514
    Abstract: A drug-eluting stent comprises a coated layer prepared of a composition comprising a polymer and a drug, the coated layer being a single coated layer with the composition, or comprises a first coated layer prepared of the above composition and a second coated layer with a polymer alone, the first coated layer being coated by the second coated layer. The drug is a vascular intimal hyperplasia inhibitor which does not inhibit proliferation of endothelial cells, and the composition substantially excludes a lipid-soluble low-molecular compound. The polymer in the first layer is a copolymer of lactic acid (monomer A) and a terminal hydroxy straight alkyl carboxylic acid having 3 to 8 carbon atoms, and, if the second coated layer is formed, the polymer in the second coated layer is a poly(lactic acid), a poly(glycolic acid), or a poly(lactic acid-co-glycolic acid).
    Type: Application
    Filed: August 25, 2011
    Publication date: December 22, 2011
    Applicant: JAPAN STENT TECHNOLOGY CO., LTD.
    Inventors: Ikuo Omura, Zhen Yu Jin
  • Patent number: 7931934
    Abstract: A medical device includes a medial device body, and a diamond-like thin film covering the medical device body and containing silicon. The diamond-like thin film has a concentration of silicon which is lower in a surface thereof than in an interface thereof with the medical device body mentioned above, and continuously varies.
    Type: Grant
    Filed: January 15, 2007
    Date of Patent: April 26, 2011
    Assignees: Toyo Advanced Technologies Co., Ltd., Japan Stent Technology Co., Ltd.
    Inventors: Tatsuyuki Nakatani, Keishi Okamoto, Shuzo Yamashita, Koji Mori, Ikuo Komura
  • Publication number: 20100198344
    Abstract: A stent includes a stent body of a cylindrical configuration having outer and inner surfaces, a first coated layer coating at least the outer surface, and a second coated layer coating substantially completely over the first coated layer. The first coated layer is prepared of a first composition comprising a polymer and a vascular intimal hyperplasia inhibitor (preferably argatroban) of a kind, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the inhibitor being within the range of 8:2 to 3:7. On the other hand, the second coated layer is prepared of a polymer alone or a second composition comprising a polymer and a drug, the weight compositional ratio of the drug to 80% by weight of the polymer being less than 20% by weight.
    Type: Application
    Filed: September 3, 2008
    Publication date: August 5, 2010
    Applicants: Japan Stent Technology Co., Ltd., Tokai University Educational System, Toyo Advanced Technologies Co., Ltd.
    Inventors: Ikuo Omura, Zhen Yu Jin, Shuzo Yamashita, Hiroo Iwata, Akira Mochizuki
  • Patent number: 7658761
    Abstract: A balloon expandable superelastic stent is made of a Ti—Ni—Nb (the content of Nb being at least 3 at %) shape memory alloy. A shape recovery temperature of the stent is lower than a living body temperature in an unloaded state after shape memory treatment. The shape recovery temperature exceeds the living body temperature after the stent is mounted to a catheter and released from the catheter in a living body.
    Type: Grant
    Filed: March 3, 2005
    Date of Patent: February 9, 2010
    Assignees: NEC Tokin Corporation, Japan Stent Technology Co., Ltd.
    Inventors: Kiyoshi Yamauchi, Kouji Mori, Shuzou Yamashita
  • Publication number: 20090131271
    Abstract: In a method for delivering a nucleic acid of the invention, a nucleic acid is introduced into a cell by pressing the nucleic acid supported on a surface of a solid substrate against the cell. According to the method, the nucleic acid can be delivered into the cell simply at a low cost without placing a heavy burden on the cell at a high nucleic acid delivery efficiency. By allowing the surface of the solid substrate to support the nucleic acid in the form of a complex with a polyamine or a cationic lipid and pressing it against the cell, the introduction efficiency into the cell can be further improved. In the invention, by using a nucleic acid useful for gene therapy as the nucleic acid, a high-efficiency device for gene therapy can be obtained.
    Type: Application
    Filed: May 16, 2006
    Publication date: May 21, 2009
    Applicants: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION, JAPAN STENT TECHNOLOGY CO, LTD.
    Inventors: Takuro Niidome, Fumio Wada, Yoshiki Katayama, Kosuke Yakumaru, Takahito Kawano, Shuzo Yamashita
  • Publication number: 20090048667
    Abstract: A drug-releasable medical device contains a controlled drug-release composition comprising 100 parts by weight of an organic polymeric material which is soluble in an organic solvent and insoluble in water, 5 to 60 parts by weight of a lipid-soluble, low molecular weight release auxiliary agent and 1 to 70 parts by weight of a drug. When the composition is applied on a stent, a catheter, an organ replacement medical device, an artificial organ or the like in the form of coating or the like, the medical device is provided with a drug release function. Argatroban or sarpogrelate hydrochloride or both of them are gradually released from the surface of a stent for treating coronary artery stenosis, for example. In order to exhibit a sustained-release function for a desired period of time, the drug to be gradually released is carried in a polymeric material coated on a surface of a metal forming the stent or in a porous stent substrate.
    Type: Application
    Filed: November 15, 2006
    Publication date: February 19, 2009
    Applicants: TOKAI UNIVERSITY EDUCATIONAL SYSTEM, JAPAN STENT TECHNOLOGY CO., LTD.
    Inventors: Akira Mochizuki, Shuzou Yamashita